Revolution Medicines (RVMD) Common Equity (2019 - 2026)

Revolution Medicines' Common Equity history runs 8 years deep, the most recent figure standing at $1.5 billion for Q1 2026.

• On a quarterly basis, Common Equity fell 27.82% year-over-year to $1.5 billion in Q1 2026; TTM through Mar 2026 was $1.5 billion, a 27.82% decrease from a year earlier, with the FY2025 full-year figure at $1.6 billion, down 27.98% from the prior year.
• Common Equity declined to $1.5 billion in Q1 2026 per RVMD's latest filing, from $1.6 billion in the prior quarter.
• Across five years, Common Equity topped out at $2.3 billion in Q4 2024 and bottomed at $498.8 million in Q2 2022.
• The 5-year median for Common Equity is $1.6 billion (2024), against an average of $1.3 billion.
• Across the five-year window, Common Equity surged 166.52% in 2023 and declined 27.98% in 2025, its largest moves.
• Year by year, Common Equity stood at $685.2 million in 2022, then jumped by 166.52% to $1.8 billion in 2023, then rose by 24.04% to $2.3 billion in 2024, then retreated by 27.98% to $1.6 billion in 2025, then dropped by 8.05% to $1.5 billion in 2026.
• Per Business Quant, the three latest RVMD Common Equity figures stand at $1.5 billion (Q1 2026), $1.6 billion (Q4 2025), and $1.6 billion (Q3 2025).